XPeng Q4 Revenue Forecast Falls Short Amid China EV Price War
XPeng's cautious Q4 outlook signals challenges ahead despite record deliveries, as China's electric vehicle price war intensifies and competition heats up.
XPeng's cautious Q4 outlook signals challenges ahead despite record deliveries, as China's electric vehicle price war intensifies and competition heats up.
Nurix Therapeutics presented positive Phase 1 data for its BTK degrader, bexobrutideg (NX-5948), showing high response rates and favorable safety in heavily pre-treated Waldenström Macroglobulinemia patients.
Wave Life Sciences' WVE-007 demonstrates 9.4% visceral fat reduction with muscle preservation in Phase 1 trial, earning positive analyst ratings and buy recommendations.
Structure Therapeutics' (GPCR) experimental obesity pill aleniglipron delivers up to 15.3% weight loss in clinical trials, positioning it as a competitive alternative to Eli Lilly's oral treatment with shares more than doubling on promising Phase 2 results.